Latest Breaking News On - Focus area approach - Page 8 : comparemela.com

FDA Approves Expanded Use of CRESEMBA® (isavuconazonium sulfate) in Children with Invasive Aspergillosis and Invasive Mucormycosis

FDA Approves Expanded Use of CRESEMBA® (isavuconazonium sulfate) in Children with Invasive Aspergillosis and Invasive Mucormycosis
kptv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kptv.com Daily Mail and Mail on Sunday newspapers.

United statesLynn fenicchiaStevens johnsonAntonioc arrietaMark reisenauerAstellas pharma us incChildren health of orangeDrug administrationAstellas pharma incBasilea pharmaceutica international ltdPrnewswire astellas pharma us incPediatric infectious diseaseSpecialties business unitMedical mycologyInvasive aspergillosisSafety information

Astellas Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone Therapy

Phase 3b DAYLIGHT study being presented at ESG 2023 demonstrated fezolinetant 45 mg achieved statistically significant reductions in the frequency and severity of moderate to severe vasomotor symptoms due to menopause and patient-reported sleep disturbance at 24 weeks Women considered unsuitable included those with contraindications, who are averse to taking, have stopped taking or have conditions that suggest caution in using hormone therapy Results will support health technology a.

Noord hollandRossella nappiNaoki okamuraSan matteo foundationUniversity of paviaEuropean society of gynecologyAstellas pharma incHead of biopharma developmentResearch centerHealth qual life outcomesAstella fezolinetant reduces frequencyWomen considered unsuitableEuropean societyFull professorReproductive medicineGynecological endocrinology

FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

/PRNewswire/ Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, "Astellas") and Seagen Inc. (Nasdaq: SGEN) today announced that on November.

United statesAhsan arozullahNaoki okamuraRoger danseyHead of oncology developmentSeagen incExchange commissionDrug administrationAmerican society of clinical oncologyMerck co incMerck sharp dohme corpEuropean society for medical oncologyNational cancer instituteAstellas pharma us incInternational agency for research on cancerAstellas pharma inc

Pfizer and Astellas XTANDI® Approved by U S FDA in Earlier Prostate Cancer Treatment Setting

/PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) today announced that the companies.

United statesChris boshoffNaoki okamuraAhsan arozullahCourtney buglerHead of oncology developmentAmerican urological association annual meetingAstellas pharma incDrug administrationOncology researchAmerican society of clinical oncologyCarolina urologic research centerPfizer incExchange commissionEuropean unionPrnewswire astellas pharma inc

Astellas Announces Data from ASPIRO Study in X-linked Myotubular Myopathy Published in The Lancet Neurology

Preliminary data analysis on ventilator dependence and motor improvement are reported alongside overall safety findings TOKYO, Nov. 15, 2023 /PRNewswire/ Astellas Pharma Inc. today announced.

University of california los angelesUnited statesSouth san franciscoSan franciscoRichard wilsonPerryb shiehNaoki okamuraPrnewswire astellas pharma incDrug administrationEuropean medicines agencyAstellas pharma incAstellas centerLancet neurologyCalifornia los angelesPrincipal investigatorSenior vice president